Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Cardiomyocyte HIPK2 Maintains Basal Cardiac Function via ERK Signaling.

Guo Y, Sui JY, Kim K, Zhang Z, Qu XA, Nam YJ, Willette RN, Barnett JV, Knollmann BC, Force T, Lal H.

Circulation. 2019 Oct 4. doi: 10.1161/CIRCULATIONAHA.119.040740. [Epub ahead of print]

PMID:
31581792
2.

Cadherin-11 blockade reduces inflammation-driven fibrotic remodeling and improves outcomes after myocardial infarction.

Schroer AK, Bersi MR, Clark CR, Zhang Q, Sanders LH, Hatzopoulos AK, Force TL, Majka SM, Lal H, Merryman WD.

JCI Insight. 2019 Sep 19;4(18). pii: 131545. doi: 10.1172/jci.insight.131545.

3.

Targeted disruption of glycogen synthase kinase-3β in cardiomyocytes attenuates cardiac parasympathetic dysfunction in type 1 diabetic Akita mice.

Zhang Y, Welzig CM, Haburcak M, Wang B, Aronovitz M, Blanton RM, Park HJ, Force T, Noujaim S, Galper JB.

PLoS One. 2019 Apr 12;14(4):e0215213. doi: 10.1371/journal.pone.0215213. eCollection 2019.

4.

Cardiomyocyte-GSK-3α promotes mPTP opening and heart failure in mice with chronic pressure overload.

Ahmad F, Singh AP, Tomar D, Rahmani M, Zhang Q, Woodgett JR, Tilley DG, Lal H, Force T.

J Mol Cell Cardiol. 2019 May;130:65-75. doi: 10.1016/j.yjmcc.2019.03.020. Epub 2019 Mar 27.

PMID:
30928428
5.

Cardiomyocyte SMAD4-Dependent TGF-β Signaling is Essential to Maintain Adult Heart Homeostasis.

Umbarkar P, Singh AP, Gupte M, Verma VK, Galindo CL, Guo Y, Zhang Q, McNamara JW, Force T, Lal H.

JACC Basic Transl Sci. 2019 Jan 16;4(1):41-53. doi: 10.1016/j.jacbts.2018.10.003. eCollection 2019 Feb.

6.

Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.

Singh AP, Glennon MS, Umbarkar P, Gupte M, Galindo CL, Zhang Q, Force T, Becker JR, Lal H.

Cardiovasc Res. 2019 Apr 15;115(5):966-977. doi: 10.1093/cvr/cvz006.

PMID:
30629146
7.

Correction: Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue.

Jacob F, Yonis AY, Cuello F, Luther P, Schulze T, Eder A, Streichert T, Mannhardt I, Hirt MN, Schaaf S, Stenzig J, Force T, Eschenhagen T, Hansen A.

PLoS One. 2018 Nov 27;13(11):e0208342. doi: 10.1371/journal.pone.0208342. eCollection 2018.

8.

Inhibition of GSK-3 to induce cardiomyocyte proliferation: a recipe for in situ cardiac regeneration.

Singh AP, Umbarkar P, Guo Y, Force T, Gupte M, Lal H.

Cardiovasc Res. 2019 Jan 1;115(1):20-30. doi: 10.1093/cvr/cvy255.

PMID:
30321309
9.

Cardiomyocyte-specific deletion of GSK-3β leads to cardiac dysfunction in a diet induced obesity model.

Gupte M, Tumuluru S, Sui JY, Singh AP, Umbarkar P, Parikh SS, Ahmad F, Zhang Q, Force T, Lal H.

Int J Cardiol. 2018 May 15;259:145-152. doi: 10.1016/j.ijcard.2018.01.013. Epub 2018 Feb 3.

10.

Rab-GTPase binding effector protein 2 (RABEP2) is a primed substrate for Glycogen Synthase kinase-3 (GSK3).

Logie L, Van Aalten L, Knebel A, Force T, Hastie CJ, MacLauchlan H, Campbell DG, Gourlay R, Prescott A, Davidson J, Fuller W, Sutherland C.

Sci Rep. 2017 Dec 15;7(1):17682. doi: 10.1038/s41598-017-17087-6.

11.

Frequency of mononuclear diploid cardiomyocytes underlies natural variation in heart regeneration.

Patterson M, Barske L, Van Handel B, Rau CD, Gan P, Sharma A, Parikh S, Denholtz M, Huang Y, Yamaguchi Y, Shen H, Allayee H, Crump JG, Force TI, Lien CL, Makita T, Lusis AJ, Kumar SR, Sucov HM.

Nat Genet. 2017 Sep;49(9):1346-1353. doi: 10.1038/ng.3929. Epub 2017 Aug 7.

12.

Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis.

Guo Y, Gupte M, Umbarkar P, Singh AP, Sui JY, Force T, Lal H.

J Mol Cell Cardiol. 2017 Sep;110:109-120. doi: 10.1016/j.yjmcc.2017.07.011. Epub 2017 Jul 27. Review.

13.

21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.

Sheng CC, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, Croce K, Kim G, Moslehi J.

JACC Basic Transl Sci. 2016 Aug;1(5):386-398. doi: 10.1016/j.jacbts.2016.05.008.

14.

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Qin P, Arabacilar P, Bernard RE, Bao W, Olzinski AR, Guo Y, Lal H, Eisennagel SH, Platchek MC, Xie W, Del Rosario J, Nayal M, Lu Q, Roethke T, Schnackenberg CG, Wright F, Quaile MP, Halsey WS, Hughes AM, Sathe GM, Livi GP, Kirkpatrick RB, Qu XA, Rajpal DK, Faelth Savitski M, Bantscheff M, Joberty G, Bergamini G, Force TL, Gatto GJ Jr, Hu E, Willette RN.

J Am Heart Assoc. 2017 May 9;6(5). pii: e004453. doi: 10.1161/JAHA.116.004453.

15.

A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.

O'Farrell AC, Evans R, Silvola JM, Miller IS, Conroy E, Hector S, Cary M, Murray DW, Jarzabek MA, Maratha A, Alamanou M, Udupi GM, Shiels L, Pallaud C, Saraste A, Liljenbäck H, Jauhiainen M, Oikonen V, Ducret A, Cutler P, McAuliffe FM, Rousseau JA, Lecomte R, Gascon S, Arany Z, Ky B, Force T, Knuuti J, Gallagher WM, Roivainen A, Byrne AT.

PLoS One. 2017 Jan 27;12(1):e0169964. doi: 10.1371/journal.pone.0169964. eCollection 2017.

16.

Response by Zhou et al to Letter Regarding Article, "Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy".

Zhou J, Ahmad F, Lal H, Force T.

Circ Res. 2016 Jul 8;119(2):e29-e30. doi: 10.1161/CIRCRESAHA.116.309093. No abstract available.

17.

Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy.

Zhou J, Ahmad F, Parikh S, Hoffman NE, Rajan S, Verma VK, Song J, Yuan A, Shanmughapriya S, Guo Y, Gao E, Koch W, Woodgett JR, Madesh M, Kishore R, Lal H, Force T.

Circ Res. 2016 Apr 15;118(8):1208-22. doi: 10.1161/CIRCRESAHA.116.308544. Epub 2016 Mar 14.

18.

Introducing JACC: Basic to Translational Science: Why Now?

Mann DL, Annex BH, Bishopric NH, Force T, Kelly DP, Libby P, Roberts R, van Rooij E, Tomaselli G, Newby LK.

JACC Basic Transl Sci. 2016 Feb 15;1(1-2):1-2. doi: 10.1016/j.jacbts.2016.01.001. eCollection 2016 Jan-Feb. No abstract available.

19.

Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue.

Jacob F, Yonis AY, Cuello F, Luther P, Schulze T, Eder A, Streichert T, Mannhardt I, Hirt MN, Schaaf S, Stenzig J, Force T, Eschenhagen T, Hansen A.

PLoS One. 2016 Feb 3;11(2):e0145937. doi: 10.1371/journal.pone.0145937. eCollection 2016. Erratum in: PLoS One. 2018 Nov 27;13(11):e0208342.

20.

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ.

Circulation. 2015 Dec 8;132(23):2248-58. doi: 10.1161/CIRCULATIONAHA.115.010484. Review.

21.

Group IVA Cytosolic Phospholipase A2 Regulates the G2-to-M Transition by Modulating the Activity of Tumor Suppressor SIRT2.

Movahedi Naini S, Sheridan AM, Force T, Shah JV, Bonventre JV.

Mol Cell Biol. 2015 Nov;35(21):3768-84. doi: 10.1128/MCB.00184-15. Epub 2015 Aug 24.

22.

A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.

Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci MA, Force T, Kelly WK.

Am J Cancer Ther Pharmacol. 2014 Sep 7;2(1):21-32.

23.

The GSK-3 family as therapeutic target for myocardial diseases.

Lal H, Ahmad F, Woodgett J, Force T.

Circ Res. 2015 Jan 2;116(1):138-49. doi: 10.1161/CIRCRESAHA.116.303613. Review.

24.

Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury.

Cross MJ, Berridge BR, Clements PJ, Cove-Smith L, Force TL, Hoffmann P, Holbrook M, Lyon AR, Mellor HR, Norris AA, Pirmohamed M, Tugwood JD, Sidaway JE, Park BK.

Br J Pharmacol. 2015 Feb;172(4):957-74. doi: 10.1111/bph.12979. Epub 2015 Jan 12. Review.

25.

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P.

Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93. doi: 10.1093/ehjci/jeu192. No abstract available.

26.

Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.

Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, Freedman A, Minasian L, Force T, Remick SC.

J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju232. doi: 10.1093/jnci/dju232. Print 2014 Sep.

27.

Heart failure: preventing disease and death worldwide.

Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G.

ESC Heart Fail. 2014 Sep;1(1):4-25. doi: 10.1002/ehf2.12005. Review.

28.

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P.

J Am Soc Echocardiogr. 2014 Sep;27(9):911-39. doi: 10.1016/j.echo.2014.07.012. No abstract available.

29.

Cardiomyocyte-specific deletion of Gsk3α mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure.

Ahmad F, Lal H, Zhou J, Vagnozzi RJ, Yu JE, Shang X, Woodgett JR, Gao E, Force T.

J Am Coll Cardiol. 2014 Aug 19;64(7):696-706. doi: 10.1016/j.jacc.2014.04.068.

30.

Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014).

Ewer M, Gianni L, Pane F, Sandri MT, Steiner RK, Wojnowski L, Yeh ET, Carver JR, Lipshultz SE, Minotti G, Armstrong GT, Cardinale D, Colan SD, Darby SC, Force TL, Kremer LC, Lenihan DJ, Sallan SE, Sawyer DB, Suter TM, Swain SM, van Leeuwen FE.

Ecancermedicalscience. 2014 May 29;8:433. doi: 10.3332/ecancer.2014.433. eCollection 2014.

31.

Imatinib activates pathological hypertrophy by altering myocyte calcium regulation.

Barr LA, Makarewich CA, Berretta RM, Gao H, Troupes CD, Woitek F, Recchia F, Kubo H, Force T, Houser SR.

Clin Transl Sci. 2014 Oct;7(5):360-7. doi: 10.1111/cts.12173. Epub 2014 Jun 16.

32.

Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart.

Lal H, Ahmad F, Zhou J, Yu JE, Vagnozzi RJ, Guo Y, Yu D, Tsai EJ, Woodgett J, Gao E, Force T.

Circulation. 2014 Jul 29;130(5):419-30. doi: 10.1161/CIRCULATIONAHA.113.008364. Epub 2014 Jun 4.

33.
34.

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

Duran JM, Makarewich CA, Trappanese D, Gross P, Husain S, Dunn J, Lal H, Sharp TE, Starosta T, Vagnozzi RJ, Berretta RM, Barbe M, Yu D, Gao E, Kubo H, Force T, Houser SR.

Circ Res. 2014 May 23;114(11):1700-1712. doi: 10.1161/CIRCRESAHA.114.303200. Epub 2014 Apr 9.

35.

MICU1 motifs define mitochondrial calcium uniporter binding and activity.

Hoffman NE, Chandramoorthy HC, Shamugapriya S, Zhang X, Rajan S, Mallilankaraman K, Gandhirajan RK, Vagnozzi RJ, Ferrer LM, Sreekrishnanilayam K, Natarajaseenivasan K, Vallem S, Force T, Choi ET, Cheung JY, Madesh M.

Cell Rep. 2013 Dec 26;5(6):1576-1588. doi: 10.1016/j.celrep.2013.11.026. Epub 2013 Dec 12.

36.

Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart.

Vagnozzi RJ, Gatto GJ Jr, Kallander LS, Hoffman NE, Mallilankaraman K, Ballard VL, Lawhorn BG, Stoy P, Philp J, Graves AP, Naito Y, Lepore JJ, Gao E, Madesh M, Force T.

Sci Transl Med. 2013 Oct 16;5(207):207ra141. doi: 10.1126/scitranslmed.3006479.

37.

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, Kaschina E, Palus S, Pötsch M, von Websky K, Hocher B, Latouche C, Jaisser F, Morawietz L, Coats AJ, Beadle J, Argiles JM, Thum T, Földes G, Doehner W, Hilfiker-Kleiner D, Force T, Anker SD.

Eur Heart J. 2014 Apr;35(14):932-41. doi: 10.1093/eurheartj/eht302. Epub 2013 Aug 29.

38.

Emerging paradigms in cardiomyopathies associated with cancer therapies.

Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ.

Circ Res. 2013 Aug 30;113(6):754-64. doi: 10.1161/CIRCRESAHA.113.300218. Review.

39.

Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55.

Yu J, Deliu E, Zhang XQ, Hoffman NE, Carter RL, Grisanti LA, Brailoiu GC, Madesh M, Cheung JY, Force T, Abood ME, Koch WJ, Tilley DG, Brailoiu E.

J Biol Chem. 2013 Aug 2;288(31):22481-92. doi: 10.1074/jbc.M113.456178. Epub 2013 Jun 27.

40.

Focusing the spotlight on GSK-3 in aging.

Zhou J, Force T.

Aging (Albany NY). 2013 Jun;5(6):388-9. No abstract available.

41.

Mechanism-based engineering against anthracycline cardiotoxicity.

Force T, Wang Y.

Circulation. 2013 Jul 9;128(2):98-100. doi: 10.1161/CIRCULATIONAHA.113.003688. Epub 2013 Jun 11. No abstract available.

42.

GSK-3α is a central regulator of age-related pathologies in mice.

Zhou J, Freeman TA, Ahmad F, Shang X, Mangano E, Gao E, Farber J, Wang Y, Ma XL, Woodgett J, Vagnozzi RJ, Lal H, Force T.

J Clin Invest. 2013 Apr;123(4):1821-32. doi: 10.1172/JCI64398. Epub 2013 Mar 15.

43.

Cancer genetics and the cardiotoxicity of the therapeutics.

Lal H, Kolaja KL, Force T.

J Am Coll Cardiol. 2013 Jan 22;61(3):267-74. doi: 10.1016/j.jacc.2012.05.066. Review.

44.

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.

McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES.

Cell Cycle. 2012 Jul 15;11(14):2747-55. doi: 10.4161/cc.21127. Epub 2012 Jul 15.

45.

Double-edged sword of the new cancer therapeutics.

Force T.

Circulation. 2012 May 1;125(17):2057-8. doi: 10.1161/CIRCULATIONAHA.112.104844. Epub 2012 Mar 26. No abstract available.

PMID:
22451582
46.

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH.

Am Heart J. 2012 Feb;163(2):156-63. doi: 10.1016/j.ahj.2011.10.018. Review.

PMID:
22305831
47.

The Heart Failure Society of America in 2020: a vision for the future.

Greenberg BH, Anand IS, Burnett JC Jr, Chin J, Dracup KA, Feldman AM, Force T, Francis GS, Houser SR, Hunt SA, Konstam MA, Lindenfeld J, Mann DL, Mehra MR, Paul SC, Piano MR, Ross HJ, Sabbah HN, Starling RC, Udelson JE, Yancy CW, Zile MR, Massie BM.

J Card Fail. 2012 Feb;18(2):90-3. doi: 10.1016/j.cardfail.2011.12.008. No abstract available.

PMID:
22300775
48.

Protein Kinase Signaling at the Crossroads of Myocyte Life and Death in Ischemic Heart Disease.

Vagnozzi RJ, Hoffman NE, Elrod JW, Madesh M, Force T.

Drug Discov Today Ther Strateg. 2012;9(4):e173-e182.

49.

Glycogen synthase kinase-3α limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death.

Lal H, Zhou J, Ahmad F, Zaka R, Vagnozzi RJ, Decaul M, Woodgett J, Gao E, Force T.

Circulation. 2012 Jan 3;125(1):65-75. doi: 10.1161/CIRCULATIONAHA.111.050666. Epub 2011 Nov 15.

50.

Wnt signaling exerts an antiproliferative effect on adult cardiac progenitor cells through IGFBP3.

Oikonomopoulos A, Sereti KI, Conyers F, Bauer M, Liao A, Guan J, Crapps D, Han JK, Dong H, Bayomy AF, Fine GC, Westerman K, Biechele TL, Moon RT, Force T, Liao R.

Circ Res. 2011 Dec 9;109(12):1363-74. doi: 10.1161/CIRCRESAHA.111.250282. Epub 2011 Oct 27.

Supplemental Content

Support Center